Introduksjon
Denne siden gir en grundig analyse av den kjente historikken for insidernes handelsaktiviteter for CPMG Inc. Insidere er ledere, direktører eller betydelige investorer i et selskap. Det er ulovlig for insidere å gjøre handler i deres selskaper basert på spesifikke, ikke-offentlig informasjon. Dette betyr ikke at det er ulovlig for dem å gjøre noen handler i deres egne selskaper. Imidlertid må de rapportere alle handler til SEC via et skjema 4. Til tross for disse begrensningene, antyder akademisk forskning at insidere - generelt sett - har en tendens til å overgå markedet i sine egne selskaper.
Gjennomsnittlig handelslønnsomhet
Den gjennomsnittlige handelslønnsomheten er den gjennomsnittlige avkastningen av alle åpne markedskjøp gjort av insideren de siste tre årene. For å beregne dette, undersøker vi hvert eneste åpne marked, uplanlagte kjøp som er gjort av insideren, men dette inkluderer ikke alle handler som ble markert som en del av en 10b5-1 handelsplan. Vi beregner deretter gjennomsnittlig ytelse av disse handlene over 3, 6 og 12 måneder, gjennomsnittlig hver av disse varighetene for å generere en endelig ytelsesmåling for hver handel. Til slutt,
Dersom lønnsomheten for denne interne handelen er "N/A", har enten den interne personen ikke gjort noen åpen-markeds kjøp de siste tre årene, eller så er handlene for nylig til å beregne en pålitelig prestasjonsmåler.
Oppdateringsfrekvens: Daglig
Selskaper med rapporterte insiderposisjoner
SEC-arkiveringene indikerer at CPMG Inc har rapporterte beholdninger av handler i følgende selskaper:
Verdipapir | Navn | Siste rapporterte høydepunkter |
---|---|---|
US:PRCT / PROCEPT BioRobotics Corporation | 10% Owner | 2 823 681 |
US:RETA / Reata Pharmaceuticals Inc - Class A | Director, 10% Owner | 0 |
US:APEN / Apollo Endosurgery Inc | 10% Owner | 0 |
Hvordan tolke diagrammene
De følgende diagrammene viser aksjens ytelse etter hver åpen markedstransaksjon som ikke var planlagt, utført av CPMG Inc. Ikke-planlagte handler er handler som ikke ble gjort som en del av en 10b5-1 handelsplan. Aksjeytelsen er kartlagt som kumulativ prosentendring i aksjekursen. For eksempel, hvis en innsidehandel ble gjort 1. januar 2019, vil diagrammet vise daglig prosentendring for verdipapiret til dagens dato. Dersom aksjeprisen går fra $10 til $15 i løpet av denne tiden, vil den kumulative prosentendringen i aksjeprisen være 50%. En endring i prisen fra $10 til $20 vil være 100%, og en endring i prisen fra $10 til $5 vil være - 50%.
Til syvende og sist er målet vårt å avgjøre hvor tett insidernes handler korrelerer med overavkastninger (positiv eller negativ) i aksjekursen for å se om insidere timer sine handler for å tjene på intern informasjon. Se for deg en situasjon der en insider gjør dette. I denne situasjonen, forventer vi enten (a) positive avkastninger etter kjøp, eller (b) negative avkastninger etter salg. I tilfelle (a) KJØP-diagrammet ville vise en serie av oppadgående kurver, som indikerer positive avkastninger etter hver kjøpstransaksjon. I tilfelle (b) ville SALG-diagrammet vise en serie av nedadgående kurver, som indikerer negative avkastninger etter hver salgstransaksjon.
Imidlertid er dette alene ikke nok til å dra konklusjoner. Hvis, for eksempel, aksjeprisen for selskapet steg jevnt over mange år uten å følge en syklisk trend, ville vi forventet at alle postkjøpsdiagrammer skal ha en stigende trend. På samme måte vil ikke-sykliske nedganger over mange år resultere i nedadgående trend i post-trade diagrammer. Ingen av disse diagrammene ville antyde aktiviteter som insidertrening.
Den sterkeste indikatoren ville vært en situasjon der aksjekursen var ekstremt syklisk, og det var både positive signaler i KJØPSdiagrammet og negative plot i SALGSdiagrammet. Denne situasjonen ville vært sterkt antydende om en insider som timet handler til sin økonomiske fordel.
Internkjøp PRCT / PROCEPT BioRobotics Corporation - Analyse av kortsiktig fortjeneste
I denne seksjonen analyserer vi lønnsomheten av hvert uplanlagt, åpen-marked internsalg som er gjort i PRCT / PROCEPT BioRobotics Corporation. Denne analysen hjelper til å forstå om den interne personen regelmessig genererer unormale avkastninger, og er verdt å følge. Denne analysen gjelder ett år etter hver handel, og resultatene er teoretiske.
Følgende tabell viser de mest nylige åpne markedskjøpene som ikke var en del av en handelsplan.
Handelsdato | Ticker | Innsider | Rapporterte aksjer |
Rapportert pris |
Justerte aksjer |
Justert pris |
Kostpris | Dager til maks |
Pris ved maks |
Maks fortjeneste ($) |
Maks fortjeneste (%) |
---|---|---|---|---|---|---|---|---|---|---|---|
2021-09-17 | PRCT | CPMG Inc | 440 000 | 25,0000 | 440 000 | 25,0000 | 11 000 000 | 357 | 50.6500 | 11 286 000 | 102,60 |
Justert pris er prisen justert for splitt. Justerte aksjer er aksjene justert for splitt.
Internhandel PRCT / PROCEPT BioRobotics Corporation - Analyse av kortsiktig tap
I denne seksjonen analyserer vi unngåelsen av kortsiktig tap for hvert uplanlagt, åpen-marked internsalg som er gjort i PRCT / PROCEPT BioRobotics Corporation. Et jevnt mønster av tap unngåelse kan antyde at fremtidige salgstransaksjoner kan forutsi nedgang i pris. Denne analysen gjelder ett år etter hver handel, og resultatene er teoretiske.
Følgende tabell viser de mest nylige åpne markedskjøpene som ikke var en del av en handelsplan.
Handelsdato | Ticker | Innsider | Rapporterte aksjer |
Rapportert pris |
Justerte aksjer |
Justert pris |
Kostpris | Dager til min |
Pris ved min |
Maks tap unngått ($) |
Maks tap unngått (%) |
---|---|---|---|---|---|---|---|
Det er ingen kjente uplanlagte handler på det åpne markedet for denne insideren og verdipapirkombinasjonen. |
Justert pris er prisen justert for splitt. Justerte aksjer er aksjene justert for splitt.
Innsidernes handelshistorikk
Tabellen viser den komplette listen over innsidehandler gjort av CPMG Inc som avslørt til Securies Exchange Comission (SEC).
Fildato | Transaksjonsdato | Skjema | Ticker | Verdipapir | Kode | Aksjer | Gjenværende aksjer | Prosent endring |
Aksje pris |
Transaksjons verdi |
Gjenværende verdi |
|
---|---|---|---|---|---|---|---|---|---|---|---|---|
2024-05-07 |
|
4 | PRCT |
PROCEPT BioRobotics Corp
Common Stock |
J - Other | −1 785 127 | 2 823 681 | −38,73 | ||||
2023-09-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
D - Sale to Issuer | −134 | 0 | −100,00 | ||||
2023-09-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
D - Sale to Issuer | −11 076 | 0 | −100,00 | ||||
2023-09-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
D - Sale to Issuer | −160 265 | 0 | −100,00 | ||||
2023-09-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
D - Sale to Issuer | −334 740 | 0 | −100,00 | ||||
2023-09-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
D - Sale to Issuer | −37 909 | 0 | −100,00 | ||||
2023-09-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
D - Sale to Issuer | −109 415 | 0 | −100,00 | ||||
2023-09-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
D - Sale to Issuer | −431 155 | 0 | −100,00 | ||||
2023-09-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
D - Sale to Issuer | −748 253 | 0 | −100,00 | ||||
2023-09-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
D - Sale to Issuer | −442 560 | 0 | −100,00 | ||||
2023-09-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
D - Sale to Issuer | −34 897 | 0 | −100,00 | ||||
2023-09-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
D - Sale to Issuer | −44 200 | 0 | −100,00 | ||||
2023-09-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
D - Sale to Issuer | −5 464 | 0 | −100,00 | ||||
2023-09-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
D - Sale to Issuer | −137 962 | 0 | −100,00 | ||||
2023-09-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
D - Sale to Issuer | −282 246 | 0 | −100,00 | ||||
2023-09-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
D - Sale to Issuer | −116 512 | 0 | −100,00 | ||||
2023-09-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
D - Sale to Issuer | −113 | 0 | −100,00 | ||||
2023-09-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
D - Sale to Issuer | −31 467 | 0 | −100,00 | ||||
2023-04-04 |
|
4 | APEN |
Apollo Endosurgery, Inc.
Common Stock |
D - Sale to Issuer | −400 675 | 0 | −100,00 | ||||
2023-04-04 |
|
4 | APEN |
Apollo Endosurgery, Inc.
Common Stock |
D - Sale to Issuer | −63 671 | 0 | −100,00 | ||||
2023-04-04 |
|
4 | APEN |
Apollo Endosurgery, Inc.
Common Stock |
D - Sale to Issuer | −45 594 | 0 | −100,00 | ||||
2023-04-04 |
|
4 | APEN |
Apollo Endosurgery, Inc.
Common Stock |
D - Sale to Issuer | −3 687 781 | 0 | −100,00 | ||||
2023-04-04 |
|
4 | APEN |
Apollo Endosurgery, Inc.
Common Stock |
D - Sale to Issuer | −1 310 701 | 0 | −100,00 | ||||
2023-04-04 |
|
4 | APEN |
Apollo Endosurgery, Inc.
Common Stock |
D - Sale to Issuer | −675 181 | 0 | −100,00 | ||||
2022-12-30 |
|
4 | APEN |
Apollo Endosurgery, Inc.
Class A common stock |
C - Conversion | 1 465 770 | 3 687 781 | 65,97 | 3,25 | 4 763 752 | 11 985 288 | |
2022-12-30 |
|
4 | APEN |
Apollo Endosurgery, Inc.
Class A common stock |
C - Conversion | 586 308 | 1 310 701 | 80,94 | 3,25 | 1 905 501 | 4 259 778 | |
2022-12-30 |
|
4 | APEN |
Apollo Endosurgery, Inc.
Class A common stock |
C - Conversion | 146 577 | 675 181 | 27,73 | 3,25 | 476 375 | 2 194 338 | |
2022-12-07 |
|
4 | PRCT |
PROCEPT BioRobotics Corp
Common Stock |
J - Other | −1 726 534 | 5 029 869 | −25,55 | ||||
2022-11-16 |
|
4 | PRCT |
PROCEPT BioRobotics Corp
Common Stock |
J - Other | −1 729 482 | 6 993 137 | −19,83 | ||||
2022-09-13 |
|
4 | PRCT |
PROCEPT BioRobotics Corp
Common Stock |
J - Other | −986 640 | 8 955 675 | −9,92 | ||||
2022-09-08 |
|
4 | PRCT |
PROCEPT BioRobotics Corp
Common Stock |
J - Other | −743 021 | 10 075 491 | −6,87 | ||||
2022-03-21 |
|
4 | PRCT |
PROCEPT BioRobotics Corp
Common Stock |
J - Other | −304 268 | 10 918 394 | −2,71 | ||||
2021-10-19 |
|
4 | APEN |
Apollo Endosurgery, Inc.
Class A common stock |
P - Purchase | 387 097 | 2 151 209 | 21,94 | 7,75 | 3 000 002 | 16 671 870 | |
2021-10-19 |
|
4 | APEN |
Apollo Endosurgery, Inc.
Class A common stock |
P - Purchase | 258 064 | 696 071 | 58,92 | 7,75 | 1 999 996 | 5 394 550 | |
2021-10-19 |
|
4 | APEN |
Apollo Endosurgery, Inc.
Class A common stock |
P - Purchase | 38 710 | 521 522 | 8,02 | 7,75 | 300 002 | 4 041 796 | |
2021-09-21 |
|
4 | PRCT |
PROCEPT BioRobotics Corp
Series G Convertible Preferred Stock |
C - Conversion | −272 205 | 0 | −100,00 | ||||
2021-09-21 |
|
4 | PRCT |
PROCEPT BioRobotics Corp
Series F Convertible Preferred Stock |
C - Conversion | −2 060 802 | 0 | −100,00 | ||||
2021-09-21 |
|
4 | PRCT |
PROCEPT BioRobotics Corp
Series E Convertible Preferred Stock |
C - Conversion | −3 038 934 | 0 | −100,00 | ||||
2021-09-21 |
|
4 | PRCT |
PROCEPT BioRobotics Corp
Series D Convertible Preferred Stock |
C - Conversion | −4 712 969 | 0 | −100,00 | ||||
2021-09-21 |
|
4 | PRCT |
PROCEPT BioRobotics Corp
Common Stock |
P - Purchase | 440 000 | 11 222 662 | 4,08 | 25,00 | 11 000 000 | 280 566 550 | |
2021-09-21 |
|
4 | PRCT |
PROCEPT BioRobotics Corp
Common Stock |
C - Conversion | 10 084 910 | 10 782 662 | 1 445,34 | ||||
2021-09-14 | 3 | PRCT |
PROCEPT BioRobotics Corp
Common Stock |
697 752 | ||||||||
2020-12-29 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
J - Other | −103 185 | 0 | −100,00 | ||||
2020-12-29 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
J - Other | −63 481 | 0 | −100,00 | ||||
2020-07-21 |
|
4 | APEN |
Apollo Endosurgery, Inc.
Class A common stock |
P - Purchase | 1 200 000 | 1 707 208 | 236,59 | 1,25 | 1 500 000 | 2 134 010 | |
2020-07-21 |
|
4 | APEN |
Apollo Endosurgery, Inc.
Class A common stock |
P - Purchase | 400 000 | 415 244 | 2 623,98 | 1,25 | 500 000 | 519 055 | |
2020-07-21 |
|
4 | APEN |
Apollo Endosurgery, Inc.
Class A common stock |
P - Purchase | 180 000 | 477 120 | 60,58 | 1,25 | 225 000 | 596 400 | |
2020-01-06 |
|
4 | APEN |
Apollo Endosurgery, Inc.
Class A common stock |
J - Other | 38 108 | 507 208 | 8,12 | ||||
2020-01-06 |
|
4 | APEN |
Apollo Endosurgery, Inc.
Class A common stock |
J - Other | 15 244 | 15 244 | |||||
2020-01-06 |
|
4 | APEN |
Apollo Endosurgery, Inc.
Class A common stock |
J - Other | 3 811 | 297 120 | 1,30 | ||||
2019-11-18 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 5 464 | 5 464 | 183,00 | 999 912 | 999 912 | ||
2019-11-18 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 27 322 | 137 962 | 24,69 | 183,00 | 4 999 926 | 25 247 046 | |
2019-11-18 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 328 | 282 246 | 0,12 | 183,00 | 60 024 | 51 651 018 | |
2019-11-18 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 7 104 | 116 512 | 6,49 | 183,00 | 1 300 032 | 21 321 696 | |
2019-08-22 | 3 | APEN |
Apollo Endosurgery, Inc.
Common Stock |
1 317 943 | ||||||||
2019-08-22 | 3 | APEN |
Apollo Endosurgery, Inc.
Common Stock |
1 565 658 | ||||||||
2019-08-22 | 3 | APEN |
Apollo Endosurgery, Inc.
Common Stock |
1 336 020 | ||||||||
2019-08-22 | 3 | APEN |
Apollo Endosurgery, Inc.
Common Stock |
1 673 024 | ||||||||
2019-08-22 | 3 | APEN |
Apollo Endosurgery, Inc.
Common Stock |
1 741 449 | ||||||||
2019-08-22 | 3 | APEN |
Apollo Endosurgery, Inc.
Common Stock |
1 317 943 | ||||||||
2019-08-22 | 3 | APEN |
Apollo Endosurgery, Inc.
Common Stock |
1 565 658 | ||||||||
2019-08-22 | 3 | APEN |
Apollo Endosurgery, Inc.
Common Stock |
1 336 020 | ||||||||
2019-08-22 | 3 | APEN |
Apollo Endosurgery, Inc.
Common Stock |
1 673 024 | ||||||||
2019-08-22 | 3 | APEN |
Apollo Endosurgery, Inc.
Common Stock |
1 741 449 | ||||||||
2019-08-22 | 3 | APEN |
Apollo Endosurgery, Inc.
Common Stock |
1 317 943 | ||||||||
2019-08-22 | 3 | APEN |
Apollo Endosurgery, Inc.
Common Stock |
1 565 658 | ||||||||
2019-08-22 | 3 | APEN |
Apollo Endosurgery, Inc.
Common Stock |
1 336 020 | ||||||||
2019-08-22 | 3 | APEN |
Apollo Endosurgery, Inc.
Common Stock |
1 673 024 | ||||||||
2019-08-22 | 3 | APEN |
Apollo Endosurgery, Inc.
Common Stock |
1 741 449 | ||||||||
2018-12-12 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 1 418 | 281 918 | 0,51 | 59,90 | 84 931 | 16 885 535 | |
2018-12-12 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 52 809 | 109 408 | 93,30 | 60,07 | 3 172 337 | 6 572 346 | |
2018-12-12 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 29 347 | 56 599 | 107,69 | 59,53 | 1 747 036 | 3 369 355 | |
2018-12-12 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 1 078 | 27 252 | 4,12 | 58,62 | 63 194 | 1 597 561 | |
2018-12-12 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 26 174 | 26 174 | 57,93 | 1 516 336 | 1 516 336 | ||
2017-12-29 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 17 000 | 44 200 | 62,50 | 28,47 | 484 016 | 1 258 440 | |
2017-12-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 200 | 27 200 | 0,74 | 26,10 | 5 220 | 709 920 | |
2017-12-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 15 000 | 27 000 | 125,00 | 25,83 | 387 444 | 697 399 | |
2017-12-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 12 000 | 12 000 | 26,06 | 312 726 | 312 726 | ||
2017-12-28 |
|
4/A | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 14 866 | 34 897 | 74,21 | 24,65 | 366 489 | 860 309 | |
2017-12-28 |
|
4/A | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 49 | 20 031 | 0,25 | 23,98 | 1 175 | 480 277 | |
2017-12-28 |
|
4/A | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 19 982 | 19 982 | 24,88 | 497 228 | 497 228 | ||
2017-12-15 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 37 492 | 431 155 | 9,52 | 24,65 | 924 283 | 10 629 178 | |
2017-12-15 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 6 245 | 103 185 | 6,44 | 24,65 | 153 957 | 2 543 799 | |
2017-12-15 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 19 672 | 748 253 | 2,70 | 24,65 | 484 970 | 18 446 532 | |
2017-12-15 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 14 866 | 477 457 | 3,21 | 24,65 | 366 489 | 11 770 652 | |
2017-12-15 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 148 | 393 663 | 0,04 | 23,98 | 3 549 | 9 438 740 | |
2017-12-15 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 59 982 | 393 515 | 17,98 | 24,88 | 1 492 580 | 9 792 149 | |
2017-12-15 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 25 | 96 940 | 0,03 | 23,98 | 599 | 2 324 301 | |
2017-12-15 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 9 990 | 96 915 | 11,49 | 24,88 | 248 589 | 2 411 613 | |
2017-12-15 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 78 | 728 581 | 0,01 | 23,98 | 1 870 | 17 468 968 | |
2017-12-15 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 31 471 | 728 503 | 4,52 | 24,88 | 783 118 | 18 127 923 | |
2017-12-15 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 49 | 462 591 | 0,01 | 23,98 | 1 175 | 11 091 406 | |
2017-12-15 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 19 982 | 462 542 | 4,52 | 24,88 | 497 228 | 11 509 803 | |
2017-06-23 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class B Common Stock |
C - Conversion | −110 640 | 0 | −100,00 | ||||
2017-06-23 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class B Common Stock |
C - Conversion | −33 656 | 0 | −100,00 | ||||
2017-06-23 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class B Common Stock |
C - Conversion | −386 285 | 0 | −100,00 | ||||
2017-06-23 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class B Common Stock |
C - Conversion | −211 708 | 0 | −100,00 | ||||
2017-06-23 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class B Common Stock |
P - Purchase | 110 640 | 110 640 | 25,00 | 2 766 000 | 2 766 000 | ||
2017-06-23 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class B Common Stock |
P - Purchase | 33 656 | 33 656 | 25,00 | 841 400 | 841 400 | ||
2017-06-23 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class B Common Stock |
P - Purchase | 386 285 | 386 285 | 25,00 | 9 657 125 | 9 657 125 | ||
2017-06-23 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class B Common Stock |
P - Purchase | 211 708 | 211 708 | 25,00 | 5 292 700 | 5 292 700 | ||
2017-06-23 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class B Common Stock |
P - Purchase | 355 591 | 993 929 | 55,71 | 25,00 | 8 889 775 | 24 848 225 | |
2017-06-23 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class B Common Stock |
P - Purchase | 102 120 | 114 946 | 796,20 | 25,00 | 2 553 000 | 2 873 650 | |
2017-06-23 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
C - Conversion | 110 640 | 110 640 | |||||
2017-06-23 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
C - Conversion | 33 656 | 86 925 | 63,18 | ||||
2017-06-23 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
C - Conversion | 386 285 | 697 032 | 124,31 | ||||
2017-06-23 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
C - Conversion | 211 708 | 442 560 | 91,71 | ||||
2017-01-04 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 2 510 | 334 740 | 0,76 | 21,72 | 54 529 | 7 272 126 | |
2017-01-04 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 2 810 | 310 747 | 0,91 | 21,72 | 61 046 | 6 750 885 | |
2017-01-04 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 1 730 | 230 852 | 0,76 | 21,72 | 37 584 | 5 015 190 | |
2017-01-04 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 480 | 63 481 | 0,76 | 21,72 | 10 428 | 1 379 106 | |
2017-01-04 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 220 | 37 909 | 0,58 | 21,72 | 4 779 | 823 562 | |
2017-01-04 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 512 | 333 533 | 0,15 | 21,72 | 11 123 | 7 245 904 | |
2017-01-04 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 1 130 | 109 415 | 1,04 | 21,72 | 24 549 | 2 377 008 | |
2016-12-20 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 42 110 | 332 230 | 14,51 | 22,99 | 968 147 | 7 638 267 | |
2016-12-20 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 64 250 | 307 937 | 26,37 | 22,99 | 1 477 165 | 7 079 749 | |
2016-12-20 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 29 040 | 229 122 | 14,51 | 22,99 | 667 656 | 5 267 721 | |
2016-12-20 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 7 990 | 63 001 | 14,52 | 22,99 | 183 697 | 1 448 450 | |
2016-12-20 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 1 330 | 37 689 | 3,66 | 22,99 | 30 578 | 866 504 | |
2016-12-20 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 20 033 | 280 500 | 7,69 | 22,99 | 460 577 | 6 448 947 | |
2016-12-16 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 579 | 290 120 | 0,20 | 22,05 | 12 767 | 6 397 088 | |
2016-12-16 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 1 290 | 243 687 | 0,53 | 22,05 | 28 444 | 5 373 250 | |
2016-12-16 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 400 | 200 082 | 0,20 | 22,05 | 8 820 | 4 411 768 | |
2016-12-16 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 110 | 55 011 | 0,20 | 22,05 | 2 425 | 1 212 982 | |
2016-12-16 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 321 | 260 467 | 0,12 | 22,05 | 7 078 | 5 743 245 | |
2016-12-16 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 1 439 | 289 541 | 0,50 | 21,37 | 30 744 | 6 186 072 | |
2016-12-16 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 2 810 | 242 397 | 1,17 | 21,37 | 60 036 | 5 178 836 | |
2016-12-16 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 1 000 | 199 682 | 0,50 | 21,37 | 21 365 | 4 266 226 | |
2016-12-16 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 270 | 54 901 | 0,49 | 21,37 | 5 769 | 1 172 965 | |
2016-12-16 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 670 | 260 146 | 0,26 | 21,37 | 14 315 | 5 558 045 | |
2016-08-18 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 34 130 | 288 102 | 13,44 | 17,32 | 591 234 | 4 990 791 | |
2016-08-18 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 35 490 | 239 587 | 17,39 | 17,32 | 614 793 | 4 150 366 | |
2016-08-18 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 23 530 | 198 682 | 13,43 | 17,32 | 407 610 | 3 441 768 | |
2016-08-18 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 4 120 | 108 285 | 3,96 | 17,32 | 71 371 | 1 875 821 | |
2016-08-18 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 6 470 | 54 631 | 13,43 | 17,32 | 112 080 | 946 373 | |
2016-08-18 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 1 822 | 36 359 | 5,28 | 17,32 | 31 563 | 629 847 | |
2016-08-18 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 46 510 | 253 972 | 22,42 | 17,26 | 802 884 | 4 384 217 | |
2016-08-18 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 48 320 | 204 097 | 31,02 | 17,26 | 834 129 | 3 523 245 | |
2016-08-18 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 32 080 | 175 152 | 22,42 | 17,26 | 553 784 | 3 023 579 | |
2016-08-18 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 5 830 | 104 165 | 5,93 | 17,26 | 100 641 | 1 798 159 | |
2016-08-18 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 8 820 | 48 161 | 22,42 | 17,26 | 152 256 | 831 384 | |
2016-08-18 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 2 498 | 34 537 | 7,80 | 17,26 | 43 122 | 596 198 | |
2016-08-18 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 18 620 | 207 462 | 9,86 | 16,21 | 301 845 | 3 363 125 | |
2016-08-18 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 19 050 | 155 777 | 13,93 | 16,21 | 308 816 | 2 525 270 | |
2016-08-18 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 12 840 | 143 072 | 9,86 | 16,21 | 208 147 | 2 319 312 | |
2016-08-18 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 3 460 | 98 335 | 3,65 | 16,21 | 56 089 | 1 594 089 | |
2016-08-18 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 3 530 | 39 341 | 9,86 | 16,21 | 57 224 | 637 749 | |
2016-08-18 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 1 100 | 32 039 | 3,56 | 16,21 | 17 832 | 519 378 | |
2016-08-09 |
|
4/A | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 99 922 | 99 922 | 11,00 | 1 099 142 | 1 099 142 | ||
2016-08-09 |
|
4/A | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 72 357 | 72 357 | 11,00 | 795 927 | 795 927 | ||
2016-08-09 |
|
4/A | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 68 912 | 68 912 | 11,00 | 758 032 | 758 032 | ||
2016-08-09 |
|
4/A | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 18 951 | 18 951 | 11,00 | 208 461 | 208 461 | ||
2016-08-09 |
|
4/A | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 16 366 | 16 366 | 11,00 | 180 026 | 180 026 | ||
2016-08-09 |
|
4/A | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 53 119 | 53 119 | 11,00 | 584 309 | 584 309 | ||
2016-08-09 |
|
4/A | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 275 047 | 332 396 | 479,60 | 11,00 | 3 025 517 | 3 656 356 | |
2016-08-09 |
|
4/A | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 64 712 | 78 205 | 479,60 | 11,00 | 711 832 | 860 255 | |
2016-08-09 |
|
4/A | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 132 614 | 160 265 | 479,60 | 11,00 | 1 458 754 | 1 762 915 | |
2016-06-30 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 34 010 | 88 920 | 61,94 | 19,75 | 671 735 | 1 756 268 | |
2016-06-30 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 24 630 | 64 370 | 61,98 | 19,75 | 486 470 | 1 271 378 | |
2016-06-30 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 23 460 | 61 320 | 61,97 | 19,75 | 463 361 | 1 211 137 | |
2016-06-30 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 5 880 | 30 163 | 24,21 | 19,75 | 116 136 | 595 752 | |
2016-06-30 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 6 450 | 16 860 | 61,96 | 19,75 | 127 395 | 333 004 | |
2016-06-30 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 5 570 | 14 573 | 61,87 | 19,75 | 110 014 | 287 833 | |
2016-06-30 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 21 690 | 54 910 | 65,29 | 19,83 | 430 074 | 1 088 766 | |
2016-06-30 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 15 700 | 39 740 | 65,31 | 19,83 | 311 303 | 787 973 | |
2016-06-30 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 14 960 | 37 860 | 65,33 | 19,83 | 296 630 | 750 696 | |
2016-06-30 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 3 690 | 24 283 | 17,92 | 19,83 | 73 166 | 481 488 | |
2016-06-30 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 4 110 | 10 410 | 65,24 | 19,83 | 81 494 | 206 412 | |
2016-06-30 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 3 550 | 9 003 | 65,10 | 19,83 | 70 390 | 178 513 | |
2016-06-30 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 310 | 33 220 | 0,94 | 19,74 | 6 119 | 655 670 | |
2016-06-30 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 220 | 24 040 | 0,92 | 19,74 | 4 342 | 474 482 | |
2016-06-30 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 210 | 22 900 | 0,93 | 19,74 | 4 145 | 451 982 | |
2016-06-30 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 50 | 20 593 | 0,24 | 19,74 | 987 | 406 448 | |
2016-06-30 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 50 | 20 593 | 0,24 | 19,74 | 987 | 406 448 | |
2016-06-30 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 60 | 6 300 | 0,96 | 19,74 | 1 184 | 124 344 | |
2016-06-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 6 770 | 259 476 | 2,68 | 19,17 | 129 814 | 4 975 426 | |
2016-06-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 5 130 | 32 190 | 18,96 | 19,17 | 98 367 | 617 240 | |
2016-06-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 3 720 | 23 820 | 18,51 | 19,17 | 71 331 | 456 746 | |
2016-06-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 3 540 | 22 690 | 18,49 | 19,17 | 67 879 | 435 078 | |
2016-06-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 990 | 20 543 | 5,06 | 19,17 | 18 983 | 393 910 | |
2016-06-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 970 | 6 240 | 18,41 | 19,17 | 18 600 | 119 651 | |
2016-06-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 848 | 5 403 | 18,62 | 19,17 | 16 260 | 103 602 | |
2016-06-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 14 386 | 27 780 | 107,41 | 19,49 | 280 390 | 541 446 | |
2016-06-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 10 418 | 20 100 | 107,60 | 19,49 | 203 052 | 391 759 | |
2016-06-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 9 921 | 19 150 | 107,50 | 19,49 | 193 365 | 373 243 | |
2016-06-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 2 712 | 19 553 | 16,10 | 19,49 | 52 858 | 381 098 | |
2016-06-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 2 728 | 5 270 | 107,32 | 19,49 | 53 170 | 102 715 | |
2016-06-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 2 360 | 4 555 | 107,52 | 19,49 | 45 998 | 88 779 | |
2016-06-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 3 014 | 13 394 | 29,04 | 18,35 | 55 307 | 245 781 | |
2016-06-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 2 182 | 9 682 | 29,09 | 18,35 | 40 040 | 177 666 | |
2016-06-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 2 079 | 9 229 | 29,08 | 18,35 | 38 150 | 169 353 | |
2016-06-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 568 | 16 841 | 3,49 | 18,35 | 10 423 | 309 034 | |
2016-06-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 572 | 2 542 | 29,04 | 18,35 | 10 496 | 46 646 | |
2016-06-28 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 495 | 2 195 | 29,12 | 18,35 | 9 083 | 40 278 | |
2016-06-08 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 1 400 | 10 380 | 15,59 | 17,62 | 24 669 | 182 905 | |
2016-06-08 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 1 010 | 7 500 | 15,56 | 17,62 | 17 797 | 132 157 | |
2016-06-08 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 970 | 7 150 | 15,70 | 17,62 | 17 092 | 125 989 | |
2016-06-08 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 340 | 16 273 | 2,13 | 17,62 | 5 991 | 286 745 | |
2016-06-08 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 270 | 1 970 | 15,88 | 17,62 | 4 758 | 34 713 | |
2016-06-08 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 230 | 1 700 | 15,65 | 17,62 | 4 053 | 29 956 | |
2016-06-08 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 6 650 | 8 980 | 285,41 | 17,56 | 116 771 | 157 685 | |
2016-06-08 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 4 810 | 6 490 | 286,31 | 17,56 | 84 462 | 113 962 | |
2016-06-08 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 4 580 | 6 180 | 286,25 | 17,56 | 80 423 | 108 518 | |
2016-06-08 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 1 610 | 15 933 | 11,24 | 17,56 | 28 271 | 279 777 | |
2016-06-08 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 1 260 | 1 700 | 286,36 | 17,56 | 22 125 | 29 851 | |
2016-06-08 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 1 090 | 1 470 | 286,84 | 17,56 | 19 140 | 25 813 | |
2016-06-03 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 625 | 57 974 | 1,09 | 13,42 | 8 387 | 778 005 | |
2016-06-03 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 830 | 14 323 | 6,15 | 13,42 | 11 139 | 192 213 | |
2016-06-03 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 2 330 | 2 330 | 13,42 | 31 268 | 31 268 | ||
2016-06-03 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 1 680 | 1 680 | 13,42 | 22 545 | 22 545 | ||
2016-06-03 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 1 600 | 1 600 | 13,42 | 21 472 | 21 472 | ||
2016-06-03 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 440 | 440 | 13,42 | 5 905 | 5 905 | ||
2016-06-03 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 380 | 380 | 13,42 | 5 100 | 5 100 | ||
2016-06-03 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 150 | 150 | 13,42 | 2 013 | 2 013 | ||
2016-06-01 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class B common stock |
C - Conversion | −134 | 1 490 | −8,25 | ||||
2016-06-01 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class B common stock |
C - Conversion | −57 349 | 638 338 | −8,24 | ||||
2016-06-01 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class B common stock |
C - Conversion | −13 493 | 150 186 | −8,24 | ||||
2016-06-01 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class B common stock |
C - Conversion | −11 076 | 123 279 | −8,24 | ||||
2016-06-01 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class B common stock |
C - Conversion | −1 153 | 12 826 | −8,25 | ||||
2016-06-01 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class B common stock |
C - Conversion | −27 651 | 307 776 | −8,24 | ||||
2016-06-01 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class B common stock |
C - Conversion | −113 | 1 251 | −8,28 | ||||
2016-06-01 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 23 890 | 252 706 | 10,44 | 14,11 | 336 997 | 3 564 721 | |
2016-06-01 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 6 203 | 228 816 | 2,79 | 14,22 | 88 218 | 3 254 198 | |
2016-06-01 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 28 797 | 222 613 | 14,86 | 13,26 | 381 989 | 2 952 939 | |
2016-06-01 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 8 233 | 193 816 | 4,44 | 13,22 | 108 815 | 2 561 647 | |
2016-06-01 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 127 691 | 185 583 | 220,57 | 12,76 | 1 629 899 | 2 368 856 | |
2016-06-01 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
P - Purchase | 56 739 | 57 892 | 4 920,99 | 11,43 | 648 305 | 661 480 | |
2016-06-01 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
C - Conversion | 134 | 134 | |||||
2016-06-01 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
C - Conversion | 57 349 | 57 349 | |||||
2016-06-01 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
C - Conversion | 13 493 | 13 493 | |||||
2016-06-01 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
C - Conversion | 11 076 | 11 076 | |||||
2016-06-01 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
C - Conversion | 1 153 | 1 153 | |||||
2016-06-01 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
C - Conversion | 27 651 | 27 651 | |||||
2016-06-01 |
|
4 | RETA |
REATA PHARMACEUTICALS INC
Class A common stock |
C - Conversion | 113 | 113 |